Cara Therapeutics reported $-23845000 in Operating Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acadia Pharmaceuticals ACAD:US USD -30866000 2.78M
Acelrx Pharmaceuticals ACRX:US USD -6632000 6.94M
Aerie Pharmaceuticals AERI:US USD -26672000 8.54M
Cara Therapeutics CARA:US USD -23845000 19.37M
Chugai Pharma 4519:JP JPY 96.89B 3.05B
Depomed DEPO:US USD 6.43M 4.36M
Endo International Ordinary Shares ENDP:US USD -636822000 1.1B
Halozyme Therapeutics HALO:US USD 80.58M 46.52M
Horizon Pharma HZNP:US USD 160.61M 72.05M
Johnson & Johnson JNJ:US USD 5.82B 18M
Neurocrine Biosciences NBIX:US USD 87.8M 103.1M
Pacira Pharmaceuticals PCRX:US USD 21.29M 9.95M
Pain Therapeutics PTIE:US USD -21345000 1.43M
Pfizer PFE:US USD 9.41B 2.69B
Revance Therapeutics RVNC:US USD -77484000 19.64M
Supernus Pharmaceuticals SUPN:US USD -1523000 12.87M
Teva Pharmaceutical Industries TEVA:US USD 419M 1.37B
Vanda Pharmaceuticals VNDA:US USD 3.91M 447K